Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2020 Dec 7

PMID 33282914

Citations 13

Authors

Sabna Kotta

Hibah Mubarak Aldawsari

Shaimaa M Badr-Eldin

Nabil Abdulhafiz Alhakamy

Shadab Md

Anroop B Nair

Pran Kishore Deb

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease-19 (COVID-19) is caused due to the infection by a unique single stranded enveloped RNA virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The COVID-19 has claimed many lives around the globe, and a promising solution to end this pandemic is still awaited. Till date neither an exact antiviral drug nor a vaccine is available in the market for public use to cure or control this pandemic. Repurposed drugs and supportive measures are the only available treatment options. This systematic review focuses on different treatment strategies based on various clinical studies. The review discusses all the current treatment plans and probable future strategies obtained as a result of a systematic search in PubMed and Science Direct database. All the possible options for the treatment as well as prophylaxis of COVID-19 are discussed. Apart from this, the article provides details on the clinical trials related to COVID-19, which are registered under ClinicalTrials.gov. Potential of drugs based on the previous researches on SARS-CoV, MERS-CoV, Ebola, influenza, etc. which fall under the same category of coronavirus are also emphasized. Information on cell-based and immunology-based approaches is also provided. In addition, miscellaneous therapeutic approaches and adjunctive therapies are discussed. The drug repurposing options, as evidenced from various and models, are also covered including the possible future solutions to this pandemic.

Citing Articles

The Role of Cyclodextrins in COVID-19 Therapy-A Literature Review.

Almeida B, Domingues C, Mascarenhas-Melo F, Silva I, Jarak I, Veiga F Int J Mol Sci. 2023; 24(3).

PMID: 36769299 PMC: 9918006. DOI: 10.3390/ijms24032974.

GDF15 : A modulator of immunity and a predictive biomarker of cardiovascular events : A strategy in COVID-19.

Rochette L, Dogon G, Rigal E, Zeller M, Vergely C, Cottin Y Ann Cardiol Angeiol (Paris). 2022; 72(1):41-43.

PMID: 36163282 PMC: 9477966. DOI: 10.1016/j.ancard.2022.09.001.

GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism.

Rochette L, Zeller M, Cottin Y, Vergely C Trends Endocrinol Metab. 2021; 32(11):875-889.

PMID: 34593305 PMC: 8423996. DOI: 10.1016/j.tem.2021.08.011.

Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS.

Kotta S, Aldawsari H, Badr-Eldin S, Binmahfouz L, Bakhaidar R, Sreeharsha N Pharmaceutics. 2021; 13(9).

PMID: 34575422 PMC: 8471313. DOI: 10.3390/pharmaceutics13091347.

Indomethacin-based PROTACs as pan-coronavirus antiviral agents.

Desantis J, Mercorelli B, Celegato M, Croci F, Bazzacco A, Baroni M Eur J Med Chem. 2021; 226:113814.

PMID: 34534839 PMC: 8416298. DOI: 10.1016/j.ejmech.2021.113814.

References

Chavez S, Long B, Koyfman A, Liang S . Coronavirus Disease (COVID-19): A primer for emergency physicians. Am J Emerg Med. 2020; 44:220-229. PMC: 7102516. DOI: 10.1016/j.ajem.2020.03.036. View

Lombardy Section Italian Society Infectious And Tropical Diseases - . Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020. Infez Med. 2020; 28(2):143-152. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Khoury M, Rocco P, Phinney D, Krampera M, Martin I, Viswanathan S . Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. Cytotherapy. 2020; 22(11):602-605. PMC: 7163352. DOI: 10.1016/j.jcyt.2020.04.089. View

Walmrath D, Gunther A, Ghofrani H, Schermuly R, Schneider T, Grimminger F . Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med. 1996; 154(1):57-62. DOI: 10.1164/ajrccm.154.1.8680699. View

Ye X, Luo Y, Xia S, Sun Q, Ding J, Zhou Y . Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020; 24(6):3390-3396. DOI: 10.26355/eurrev_202003_20706. View

Li L, Li Y, Zhang L, Hou T . Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase. J Chem Inf Model. 2012; 52(10):2715-29. DOI: 10.1021/ci300375k. View

Bakhtawar N, Usman M, Khan M . Convalescent Plasma Therapy and Its Effects On COVID-19 Patient Outcomes: A Systematic Review of Current Literature. Cureus. 2020; 12(8):e9535. PMC: 7465934. DOI: 10.7759/cureus.9535. View

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

10.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

11.

Blaising J, Polyak S, Pecheur E . Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014; 107:84-94. PMC: 7113885. DOI: 10.1016/j.antiviral.2014.04.006. View

12.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

14.

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

15.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

16.

Raha S, Mallick R, Basak S, Duttaroy A . Is copper beneficial for COVID-19 patients?. Med Hypotheses. 2020; 142:109814. PMC: 7199671. DOI: 10.1016/j.mehy.2020.109814. View

17.

Shannon A, Le N, Selisko B, Eydoux C, Alvarez K, Guillemot J . Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020; 178:104793. PMC: 7151495. DOI: 10.1016/j.antiviral.2020.104793. View

18.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View

19.

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

20.

Spezzani V, Piunno A, Iselin H . Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple. Swiss Med Wkly. 2020; 150:w20246. DOI: 10.4414/smw.2020.20246. View